Definitive Contract 75F40121C00150
Award Date 9/24/21
Potential Completion Date 9/26/26
Potential Value $1.4M
Federal Agency
Awardee
Ultimate Awardee
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Cost No Fee
Place of Performance
Silver Spring, MD 20993, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
10
Legislative Mandate
Employment Eligibility Verification
National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- This is a $973,150.35 definitive, firm fixed price contract awarded by the Food and Drug Administration (FDA) to the University of Connecticut (UConn) for a study on the "Impact of Polymer Attributes on the Performance of In Situ Forming Implants." The contract has a completion date of September 9, 2023 and was awarded on March 6, 2020. UConn, a non-profit educational institution, will leverage its expertise in scientific research and specialized services to support this FDA study....
- This is a $1,103,886.00 Firm Fixed Price contract awarded by the Food and Drug Administration (FDA), a civilian agency, to the University of Connecticut (UConn) to conduct research and development on the "Impact of API CQAS on In Situ Forming Implants and Understanding In Vitro and In Vivo Performance Differences". The contract has a completion date of September 29, 2026 and was awarded on September 22, 2023 with no set-aside designation. UConn is a prominent 1862 land-grant...
- This is a $1,530,889.00 definitive contract awarded by the Food and Drug Administration (FDA) to the University of Connecticut (UConn) to conduct a research study titled "Investigating the Impact of API Purity, Excipient Source and Manufacturing Process on Performance and Quality of Complex siRNA Lipid Nanoparticles". The contract has a performance period ending on September 21, 2027 and is a cost-type contract with no fee. UConn, a non-profit 1862 land-grant university, has...
- This is a $219,991 cost-no-fee definitive contract awarded by the Food and Drug Administration (FDA) to the University of Connecticut (UConn) to conduct research on the "Continuous Manufacturing of Liposomes: Materials Understanding and Process Control." The contract is part of the FDA's broader program on continuous manufacturing of liposomes, a type of drug delivery system. UConn, a leading public research institution, will leverage its expertise in materials science, engineering,...
- This is a definitive contract awarded by the Department of Health and Human Services Food and Drug Administration to the University of Connecticut for "Assessing Long-Acting Injectable Formulations Using In Vivo Imaging". The potential value of the contract is $1,131,742.00 and it has a completion date of September 29, 2024. The contract is not set aside for a specific business category. Under this contract, the University of Connecticut is conducting research and analysis on...
- The University of Connecticut has been awarded a definitive contract by the Department of Health and Human Services Food and Drug Administration to continue processing liposomal nanoparticles as reference materials for drug product development. With a potential value of $349,364, this time and materials contract does not have a set-aside designation and is to be completed by May 31, 2023. As the prime contractor, the University will utilize its expertise in nanotechnology and materials...
- The University of Connecticut (UConn) was awarded a $1,310,263 cost-no-fee definitive contract by the Food and Drug Administration (FDA) to enhance and validate in vitro-in vivo correlation (IVIVC) methods for long-acting injectable drug products to accelerate their generic development. The contract is part of the FDA's Broad Agency Announcement for Advanced Regulatory Science, which solicits research and development proposals across various areas to modernize regulatory science and support...
- This is a $1,484,606.68 definitive contract awarded by the Food and Drug Administration (FDA) to the Regents of the University of Michigan to conduct research and analysis on stimulant use, misuse, and use disorder trajectories. The contract has no set-aside designation. Under the contract, the University of Michigan will coordinate with Massachusetts General Hospital and Texas State University to supplement existing drug use and health survey data with clinical data from the MGH's HEAL project....
- The Department of Health and Human Services Food and Drug Administration awarded a $249,999.00 definitive contract to Hartford Hospital, a non-profit hospital organization, to conduct research and development in support of regulatory science and innovation. This contract was awarded under the FDA's Broad Agency Announcement for Advanced Regulatory Science for fiscal year 2021, which solicits proposals across eight areas of regulatory science to modernize FDA functions. The contract does not have...
- This is a federal contract awarded by the Food and Drug Administration (FDA) to Mental Health & Addiction Services Conne, a U.S. state government entity within the Connecticut Department of Mental Health and Addiction Services. The contract, valued at $1,502,034.74, is for a Delivery Order under an Indefinite Delivery Contract (IDC) to conduct tobacco retail inspections across the state of Connecticut. The purpose is to support the FDA's enforcement of the Tobacco Control Act. This...